Plain-English translation of NCT05841550 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new vaccine called /QS-21 to see if it can help treat multiple myeloma—a blood cancer—in patients whose cancer cells have a specific genetic mutation. The vaccine works by training your immune system to recognize and fight the cancer cells. The study will measure whether the treatment is safe, whether patients tolerate it well, and whether it helps slow or stop cancer growth.
Multiple myeloma is a serious blood cancer that can come back or progress even after treatment. Researchers hope this medication will offer a new way to help patients whose tumors have this particular genetic change, potentially giving them more treatment options and better outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive 12 injections of the medication over the first 12 weeks—one shot every 2 weeks—followed by additional injections every 8 weeks until week 52 (about one year total). Each injection is given under the skin. Throughout the study, you will have blood tests and doctor visits to check how you are tolerating the treatment and whether it is working to control your cancer.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Norway